Date: 2012-06-05

Type of information:

Product name: TB-403 (RG7334)

Compound: TB-403 (RG7334)

Therapeutic area:

Action mechanism: TB-403 is a humanized monoclonal antibody directed towards placental growth factor (PIGF), expected to act by blocking the formation of the new blood vessels that are required for tumour growth. Preclinical exploration of PIGF biology suggests a role in tumour angiogenesis and metastasis and a limited role in the maintenance of normal vasculature. This mode of action could result in therapeutic benefit with an acceptable side effect profile. Two phase I clinical trials have found that TB-403 was well tolerated with no reported dose limiting toxicity.

Company: BioInvent (Sweden) Thrombogenics (Belgium)


Latest news:

* On June 5, 2012, BioInvent International and co-development partner ThromboGenics have announced that they will regain global rights to TB-403 from Roche.
TB-403 was licensed to Roche in 2008. ThromboGenics and BioInvent plan to further evaluate the potential of TB-403 in certain cancer and non-cancer indications, including ophthalmology. Clinical studies with TB-403 to-date have shown that it is safe and well tolerated. Roche’s decision was due to the prioritization of resources in the Roche portfolio. Roche had initiated several clinical studies with TB-403 (RG7334)  [a phase Ib/II study in patients with glioblastoma multiforme (See, an imaging study in patients with colorectal and ovarian cancer and a phase Ib study of TB-403 in patients with primary liver cancer (hepatocellular carcinoma].
The partners will now evaluate TB-403 potential in other cancer and non cancer indications as  retinal diseases including diabetic retinopathy and AMD.


Submission of marketing authorization application USA :

Submission of marketing authorization application UE:

Withdrawal of marketing authorization application USA:

Withdrawal of marketing authorization application UE:

US authorization:

UE authorization:

Favourable opinion UE:

Favourable opinion USA:

Orphan status USA:

Orphan status UE:

Pediatric exclusivit _USA:

Pediatric exclusivity UE:

OTC status:

Other news:

Is general: Yes